Single contract, the record!

logo-sante-publique-france

As you are all aware, the single contract has been in place since the ministerial instruction of 17 June 2014 in public health institutions. We talked about it in our article entitled “Hospital Single contract: real benefit for French clinical research”.

Although not compulsory, public health institutions were strongly encouraged to use this new contract by setting up specific credits. Since then, orders have been issued for this single contract. Let’s take a look at what has changed since 2014.

Small reminder: We are not lawyers. If you would like further analysis of these texts, we recommend that you contact a specialist lawyer or do a specific training on this subject. We cannot be held responsible for the misinterpretation of these texts.

The law has recently evolved with the publication of two texts:

Concretely, the following changes were made to the publication of this decree:

contrat-unique-bilan-1

contrat-unique-bilan-2

contrat-unique-bilan-3

As you will have understood, the convention model has been amended. We discover new notions such as:

  • Third-party structures: Structure “participating in research but not under the authority of the legal representative of the institution or the house or health center where the research is also taking place. Compensations may be granted only if the third party structure fulfills the following conditions:

“1° It is designated by the legal representative of the health institution, the house or the health center in accordance with the law of public order, if necessary;

“2° It has a governance that is capable of protecting it and its management from the risk of calling into question their liability, particularly with regard to the risk of conflict of interest or the violation of the principles and rules for the protection of persons involved in research;

“3° It uses the funds received from the promoter for research purposes. »1

These structures may receive all or part of the compensations paid by the promoter, if desired. As a reminder, a compensation is paid “for the expected quality of the research data”1 by the promoter at the center. The quality of this third structure is not specified, we can therefore imagine paying this compensation to an association.

  • “Costs” and “Additional costs”: the new version of the agreement incorporates the notion of “Costs” which was not present in the previous version of the agreement. Indeed, we were only talking about “extra costs”.

The given definition is the following:

“The Costs shall consist of all other additional costs related to the implementation of the Protocol, including the investigative tasks required for the Research and the administrative and logistical tasks related to the Research.”

This notion was previously integrated into the Additional Costs, so it is only a change of vocabulary. The additional costs retain the same definition, namely costs “related to the care of the patient or the healthy volunteer and required by the implementation of the Protocol. These are the acts necessary for the Research in addition to those mentioned in the recommendations of the Good Clinical Practices validated by the High Authority of Health for the care in question, where they exist, and which cannot be the subject of billing for health insurance to the patient2. The Good Clinical Practices in question in this section are the practices recommended by the HAH for the patient care and not the GCP of clinical research.

Finally, it should be noted that this single agreement “shall be exclusive of any other contract for consideration for commercial research in the concerned health institution, home or health center1, which means that there can be no other contract such as a contract with the investigator.

Finally, please note that article L.1122-1 of the Public Health Code has also been updated. From now on, it is necessary to inform the patient of the methods of payment of the compensations related to the expected quality of the data resulting from the research which could be paid to a third structure.

“6° bis For commercial researches, the terms and conditions for the payment of compensations in addition to the support of additional research-related costs, where applicable, under the conditions laid down in Article L. 1121-16- 1;3

Concretely, it will be necessary to verify that your information notes to the patient contain the requested information: a third-party structure, to be specified, will receive financial compensation paid by the promoter and linked to the expected quality of the research data.

The single convention will therefore definitely enter into practice in France since it will concern all institutions, centers and health care homes. It appears that this contract has been adopted by several public institutions, so it is necessary to continue this process in order to reduce the time taken to negotiate contracts.

Sources:

  1. Decree n°. 2016-1538 of 16 November 2016 on the single convention for the implementation of commercial research involving the human person in health care institutions, homes and health centers: available here.
  2. Article L. 1121-1 of the Code of Public Health
  3. Article L.1122-1 of the Code of Public Health

Written by Sophie Hammer

 

Merci d'avoir lu cet article!

Pour aller plus loin, tu peux recevoir gratuitement tes guides

"Comment se former et trouver un emploi d'ARC?"

"Menez une étude clinique au succès"

ebooks_2018_photo.PNG
Recherches utilisés pour trouver cet article :convention unique recherche clinique questions,recensement contrat unique,contrat unique convention hospitaliére,recherche clinique negociation de contrat,contrat unique,negociation contrat recherche clinique,single contrat,convention unique recherche clinique et contre partie,convention unique recherche clinique,contrat unique recherche clinique negociation

7 thoughts on “Single contract, the record!

  1. Anne Marie Denys

    Bonjour,

    Je vous contacte de la Belgique et j’aimerai bien recevoir votre aide sur la convention.
    Il s’agit d’une étude interventionel académique, international, de phase II avec randomisation entre deux bras sur un médicament experimental. Le promoteur de l’étude clinique se trouve au Pays-Bas. Un centre (un hôpital) participe en France. La convention (je parle donc du contrat financier) n’est pas le contrat unique mais le contrat venant du promoteur. Entre temps l’étude à été approuvé par l’ANSM et nous attendons l’accord du CPP (une petite formalité à finir). Le contrat est également signé par les deux parties (le promoteur et le médecin participant). Est-ce que ce contrat doit être soumis auprès du CNOM et devons nous recevoir leur accord avant de pouvoir débuter l’étude? Comment faut t’il soumettre? Je ne trouve nulle part des instructions à ce sujet.

    Bien cordialement,
    Anne Marie

    Reply
    1. Vanessa Montanari

      Bonjour,

      Pour nous, oui. Seul le contrat unique ne doit pas être soumis car il s’agit d’un modèle fixé par la loi et qui n’est modifié.
      Peut-être que vous pouvez contacter directement le CNOM par téléphone pour leur poser la question ?

      A bientôt,

      Vanessa

      Reply
    2. Anne Marie Denys

      Merci pour votre réponse, entre temps j’ai eux des discussions avec le centre qui est persuadé que le contrat ne doit pas être soumis au CNOM puisqu’il s’agit d’une étude académique. Ils ont discuté en interne, avec entre autres la direction de l’hôpital, et ils ce sont mis d’accord que le contrat ne doit pas être soumis auprès du CNOM.

      Bien cordialment
      Anne-Marie

      Reply
      1. Vanessa Montanari

        Bonjour,

        J’aurai tout de même appelé le CNOM car cela ne coûte rien mais c’est à vous de voir.
        Merci,

        Vanessa

        Reply
  2. emile

    Bonjour

    Avant le démarrage d’une étude, et généralement au moment de l’établissement du contrat, il faut informer la direction (directeur/directrice) de l’hôpital. Quelle est, actuellement, la méthode à utiliser? Envoyer un courrier? Mais dans ce cas nous n’avons pas de preuve d’envoi… ou peut -on de permettre d’envoyer un mail directement au directeur (vu que les adresses sont disponibles sur le site de l’hôpital)?
    Je trouve le mail plus moderne, pratique et cela constitue une vraie preuve d’envoi…mais je trouve cela gênant d’écrire directement sur leur boite mail (et en même temps je n’ai pas le mail des assistants)… Quelle est la méthode habituelle?

    Merci

    Reply
    1. Vanessa Montanari

      Bonjour,

      Faites un courrier postal à la pharmacie et à la direction avec un accusé de réception en accord avec le texte de loi sur l’information de la direction et de la pharmacie hospitalière sur la mise ne place de l’étude clinique (tous les textes de loi sont dans le mémento sur les recherches impliquant la personne humaine – procurez vous en un).

      Merci,

      Vanessa

      Reply
  3. Anne

    Bonjour à tous,
    Je souhaiterais avoir cotre avis sur le contrat unique.
    Quelqu’un sait-il combien de temps il faut prévoir entre les débuts des négociation et la signature du contrat final? pour le centre coordinateur? pour les centres associés?
    Le contrat unique est-il maintenant utilisé par les centres privés?

    Merci d’avance pour vos retours d’expérience

    Très bonnes fêtes de fin d’année

    Reply

Leave a Reply

Your email address will not be published.

This blog is kept spam free by WP-SpamFree.